Relevium Acquires Exclusive Licence From California Based Cannakids®

World News: . []

MONTREAL, May 30, 2019 (GLOBE NEWSWIRE) -- Inc. (TSX.V:”, OTCQB:“” and Frankfurt: ”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned subsidiary Biocannabix Health Corporation Inc., has completed necessary compliance process and obligations for the acquisition for exclusive licensing with cannabis company Cannakids®.

Aurelio Useche, CEO stated: “According to Tecnavio2018, the global pediatric market for medicines will reach 121 billion by 2021 and we intend to lead the way in Endo-Medicinal Nutraceuticals.” Mr. Useche stated further: “We are delighted to have completed this lengthy process and very keen to start working towards building the pathway to the full commercialization of Pediatric Endo-Medicinal Nutraceuticals in partnership with Cannakids®.”

The licensing agreement between Biocannabix and Cannakids® grants the exclusive Canadian rights to the CannaKids IP including formulations, SOPs, dosing, titration and patient data with a Royalty on sales of 13%.

Tracy Ryan, CEO of Cannakids®, stated: “The Cannakids team is ecstatic to now be extending our reach into Canada. It has always been our goal to help patients on a global scale, and we are proud to have Relevium as our Canadian partner to help us take that next step in making our dreams a reality. We look forward to helping Canadians find holistic relief from their ailments, all while working towards expanding our research to patients both, young and old.”

Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the Health and Wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as and

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

On Behalf of the Board of Directors

For more information about this press release: Tel: +1.888.528.8687

Email: Website:

More news and information about Relevium Technologies Inc

Published By:

Globe Newswire: 13:00 GMT Thursday 30th May 2019

Published: .

Search for other references to "relevium" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us